Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis

Abstract Introduction Baricitinib, an orally available small-molecule inhibitor of Janus kinase (JAK)1 and JAK2, is indicated to treat active moderate-to-severe rheumatoid arthritis (RA). Objective This systematic review described the real-world clinical characteristics of baricitinib-treated patien...

Full description

Bibliographic Details
Main Authors: Blanca Hernández-Cruz, Uta Kiltz, Jérôme Avouac, Tamas Treuer, Ewa Haladyj, Jens Gerwien, Chandreyee Dutta Gupta, Fabrizio Conti
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-09-01
Series:Rheumatology and Therapy
Subjects:
Baricitinib
Real-world evidence
Janus kinase inhibitors
Rheumatoid arthritis
Online Access:https://doi.org/10.1007/s40744-023-00591-9

Internet

https://doi.org/10.1007/s40744-023-00591-9

Similar Items